Abstract 575P
Background
The data for dacomitinib, a second-generation EGFR-TKI, treating patients with advanced non-small cell lung cancer (NSCLC) and brain metastasis was lacking. This study aimed to explore the efficacy and safety of dacomitinib in treating EGFR-mutated advanced NSCLC with brain metastasis in first-line settings.
Methods
Eligible patients were treatment-naïve advanced NSCLC patients with ≥1 brain metastasis no less than 5mm treated with dacomitinib. The primary endpoint was intracranial objective response rate (iORR). Secondary endpoints included intracranial progression-free survival (iPFS), intracranial disease control rate (iDCR), sytemic ORR and DCR, PFS, overall survival (OS), and safety. Response was evaluated per modified Response Evaluation Criteria in Solid Tumors (mRECIST, version 1.1) and Response Assessment in Neuro-oncology, Leptomeningeal Metastasis (RANO-LM) criteria.
Results
Between Jul 2nd, 2019, and Sep 30th, 2022, a total of 87 treatment-naïve patients from four hospitals were included. Data cutoff date was Mar 24th, 2023. Median follow-up time was 17.5 (1.6-34.7)months. For 87 patients with evaluable brain metastasis, iORR was 89.7% and iDCR was 97.7%per mRECIST criteria. Based on RANO-LM criteria, iORR was 71.3% and iDCR was 97.7%. Median iPFS was 26.0 months, and the 1-year and 2-year iPFS rate were 68.9% and 51.5%, respectively. For 75 patients with evaluable extracranial lesions, systemic ORR was 73.8% and DCR was 96.4%. Systemic median PFS was 14.0 months and median OS was 34.0 months (Table). Overall, 86 of 87 (98.9%) patients experienced adverse events (AEs) of any grade. Most AEs were grade 1-2 and no patients died due to severe AEs. The most common (≥20%) AEs included rash (89.7%), oral ulcer (74.2%), diarrhea (67.8%), paronychia (59.8%). Table: 575P
Summary of intracranial and systemic efficacy
| Intracranial efficacy (N=87) | Systematic efficacy (N=75) | ||
| per mRECIST criteria | per RANO-BM criteria | ||
| Complete response, n (%) | 42 (48.3) | 42 (48.3) | 2 (2.7) |
| Partial response, n (%) | 36 (41.8) | 20 (23.0) | 51 (68.0) |
| Stable disease, n (%) | 7 (8.0) | 23 (26.4) | 21 (28.0) |
| Objective response rate(95%CI) | 89.7 (81.3-95.2) | 71.3 (60.6-80.5) | 73.8 (63.1-82.8) |
| Disease control rate (95%CI) | 97.7 (91.9-99.7) | 97.7 (91.9-99.7) | 96.4 (89.9-99.3) |
| Progression-free survival, median (95%CI) | 26.0 (22.5-29.5) | 14.0 (11.1-16.9) | |
| One-year progression-free survival rate | 68.9% | 53.1% | |
| Two-year progression-free survival rate | 51.5% | 24.1% |
Conclusions
Dacomitinib showed promising efficacy and manageable safety profile for advanced NSCLC with brain metastasis harboring EGFR mutation in the first-line treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
392TiP - A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy
Presenter: Juyi Wen
Session: Poster Display
Resources:
Abstract
397P - Comparison between Y-site co-infusion versus standard dexamethasone for preventing hypersensitivity reactions from oxaliplatin administration: A randomized controlled trial
Presenter: jarearnjit Phavirunsiri
Session: Poster Display
Resources:
Abstract
398P - Evaluation of the effectiveness of denosumab therapy giant cell tumor of the pelvis
Presenter: Abbos Nurjabov
Session: Poster Display
Resources:
Abstract
399P - Long-term outcomes of patients with gastric cancer who received the best supportive care without any anticancer treatment
Presenter: Yohei Arihara
Session: Poster Display
Resources:
Abstract
401TiP - Oral opioid vs intravenous patient-controlled analgesia (PCA) with hydromorphone bolus-only or continuous infusion to maintain analgesia for severe cancer pain: A randomized phase III trial
Presenter: Cheng Huang
Session: Poster Display
Resources:
Abstract
407P - K-TrackTM: A streamlined personalized assay to detect molecular residual disease in solid tumors
Presenter: Nam Vo
Session: Poster Display
Resources:
Abstract
408P - Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
410P - Systematic evaluation of cell-free DNA fragmentation patterns for cancer diagnosis and enhanced cancer detection through integration of multiple fragmentations
Presenter: Xiangy-Yu Meng
Session: Poster Display
Resources:
Abstract
412P - Multiplex digital spatial profiling (DSP) of protein reveals distinct immune and molecular phenotypes in hepatocellular carcinoma
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
413P - Clinical utility of advanced features provided by circulating tumor DNA-based comprehensive genomic profiling
Presenter: Young-gon Kim
Session: Poster Display
Resources:
Abstract